Retail prices for 260 widely used brand-name prescription drugs last year increased by an average 2.9%, more than twice the general rate of inflation, according to a report released yesterday by AARP’s Public Policy Institute.
 
“Increases in the retail price of brand name prescription drugs have a corresponding impact on the cost of therapy for the individual and for all other payers,” the authors note. “In 2020, the average cost of therapy for a brand name prescription drug, based on the market basket in this study, was $6,600 per year.”
 
A second AARP PPI analysis found that Medicare Part D spent nearly $40 billion more on 50 top brand-name drugs between 2015 and 2019 because drug price increases exceeded inflation.

 

Related News Articles

Headline
A new report released today by the Department of Health and Human Services outlines the Biden Administration’s plans to address high drug prices. The…
Headline
President Biden today urged Congress to allow Medicare to negotiate prescription drug prices and cap the amount beneficiaries pay out-of-pocket for drugs each…
Headline
The Senate Judiciary Committee Subcommittee on Competition Policy, Antitrust, and Consumer Rights yesterday held a hearing on surging drug prices and…
Headline
Fourteen leading U.S. drug companies from 2016 to 2020 spent $577 billion on stock buybacks and dividends, $56 billion more than they spent on research…
Headline
The Department of Health and Human Services today withdrew requests for proposals on ways individuals could import prescription drugs from other countries…
Headline
The AHA July 2 expressed support for the Drug-Price Transparency for Consumers Act of 2021 (S.2304).    “America’s hospitals and health systems are…